Investors Purchase High Volume of Revolution Medicines Call Options (NASDAQ:RVMD)

Key Points

• Traders purchased an unusually high volume of call options—about 8,752 contracts, roughly 22% above the daily average—signaling short‑term speculative bullish bets on RVMD.
• A late‑stage Phase 3 trial for daraxonrasib showed nearly doubled survival in pancreatic cancer, prompting major media coverage and driving the stock to fresh highs (around $144) on heavy volume.
• At the same time, Revolution announced proposed offerings of $750M in common stock and $250M in convertible notes, creating potential dilution that could temper the rally.

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors acquired 8,752 call options on the stock. This is an increase of 22% compared to the typical daily volume of 7,156 call options.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on RVMD shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. Wedbush reaffirmed an "outperform" rating on shares of Revolution Medicines in a research report on Tuesday. Truist Financial raised shares of Revolution Medicines to a "strong-buy" rating in a research report on Wednesday, March 25th. Evercore reaffirmed an "outperform" rating on shares of Revolution Medicines in a report on Tuesday. Finally, Benchmark reiterated an "overweight" rating on shares of Revolution Medicines in a report on Tuesday, February 17th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Revolution Medicines currently has a consensus rating of "Buy" and a consensus target price of $78.94.

Insider Buying and Selling

In other news, insider Lin Wei sold 2,073 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $206,222.04. Following the completion of the sale, the insider owned 101,366 shares of the company's stock, valued at $10,083,889.68. This represents a 2.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jack Anders sold 2,753 shares of Revolution Medicines stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $273,868.44. Following the transaction, the chief financial officer owned 125,512 shares in the company, valued at $12,485,933.76. The trade was a 2.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 64,592 shares of company stock worth $6,488,732. Corporate insiders own 8.20% of the company's stock.

Institutional Trading of Revolution Medicines

Several hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. increased its stake in shares of Revolution Medicines by 1.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company's stock valued at $802,000 after purchasing an additional 125 shares during the period. Deutsche Bank AG grew its holdings in Revolution Medicines by 0.4% in the 4th quarter. Deutsche Bank AG now owns 32,217 shares of the company's stock worth $2,566,000 after buying an additional 130 shares in the last quarter. Signaturefd LLC increased its position in Revolution Medicines by 33.1% in the 4th quarter. Signaturefd LLC now owns 656 shares of the company's stock valued at $52,000 after acquiring an additional 163 shares during the period. Allworth Financial LP raised its stake in Revolution Medicines by 57.2% during the 4th quarter. Allworth Financial LP now owns 577 shares of the company's stock valued at $46,000 after acquiring an additional 210 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its position in Revolution Medicines by 44.7% during the 4th quarter. Farther Finance Advisors LLC now owns 751 shares of the company's stock worth $60,000 after acquiring an additional 232 shares during the period. 94.34% of the stock is currently owned by institutional investors.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Late‑stage trial success — Company reported daraxonrasib (pancreatic cancer) nearly doubled typical survival and cut risk of death materially in a Phase 3 study, the core catalyst for today’s rally. Reuters: Trial Results
• Positive Sentiment: Market reaction and media coverage — Major outlets reported the trial as a breakthrough and the stock soared to fresh highs as investors priced in commercial and regulatory upside. Barron's: Stock Soars
• Positive Sentiment: Unusual options buying — Traders picked up ~8,752 call contracts (about +22% vs. average), signaling speculative bullish bets and added short‑term buying pressure (no direct link available).
• Positive Sentiment: Analyst support — Wedbush reaffirmed an "outperform" rating, which reinforces buy‑side conviction amid the data momentum. Benzinga: Wedbush Reaffirmation
• Neutral Sentiment: Street debate on sustainability of move — Some analysts note the data is impressive but caution that further upside depends on regulatory pathway, labeling, payor uptake and broader competitive landscape. Seeking Alpha: Further Upside Debate
• Negative Sentiment: Planned equity and debt raise — Revolution announced proposed offerings of $750M in common stock and $250M of convertible senior notes (plus underwriter options). That potential dilution and increased share supply could weigh on the stock after the initial spike. GlobeNewswire: Offerings Announcement

Revolution Medicines Stock Performance

NASDAQ:RVMD traded up $8.04 during trading hours on Tuesday, reaching $144.34. 4,038,987 shares of the stock were exchanged, compared to its average volume of 3,300,726. Revolution Medicines has a 52 week low of $34.00 and a 52 week high of $144.41. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $28.60 billion, a P/E ratio of -24.44 and a beta of 1.01. The firm has a 50 day simple moving average of $98.90 and a 200-day simple moving average of $83.55.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same quarter in the previous year, the company posted ($1.12) EPS. As a group, sell-side analysts forecast that Revolution Medicines will post -3.49 earnings per share for the current fiscal year.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.